An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 209478
Company: CMP DEV LLC

Products on NDA 209478

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CAROSPIR	SPIRONOLACTONE	25MG/5ML	SUSPENSION;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 209478

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
08/04/2017	ORIG-1	Approval	Type 3 - New Dosage Form	STANDARD; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209478s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209478Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209478Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/24/2023	SUPPL-6	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209478s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209478Orig1s006ltr.pdf
06/25/2021	SUPPL-3	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209478s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209478Orig1s003ltr.pdf
07/15/2021	SUPPL-2	Manufacturing (CMC)-Packaging	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209478Orig1s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209478Orig1s002ltr.pdf

Labels for NDA 209478

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
08/24/2023	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209478s006lbl.pdf
07/15/2021	SUPPL-2	Manufacturing (CMC)-Packaging	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209478Orig1s002lbl.pdf
06/25/2021	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209478s003lbl.pdf
08/04/2017	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209478s000lbl.pdf

Therapeutic Equivalents for NDA 209478

CAROSPIR

SUSPENSION;ORAL; 25MG/5ML
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CAROSPIR	SPIRONOLACTONE	25MG/5ML	SUSPENSION;ORAL	Prescription	Yes	AB	209478	CMP DEV LLC
SPIRONOLACTONE	SPIRONOLACTONE	25MG/5ML	SUSPENSION;ORAL	Prescription	No	AB	215572	AMNEAL

Top